CDKN2A and hydrops fetalis: Western blotting showed that treating HF-MSCs that were ectopically expressing NANOG with this compound significantly reduced PBX1 expression to 69.38 ± 6.62% of control levels (P < 0.01) but increased the expression of p16, p53, and p21 to 162.91 ± 19.72% (P < 0.05), 123.43 ± 6.25% (P < 0.05), and 160.99 ± 9.29% (P < 0.01) of control levels, respectively.